Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections

American Journal of Medicine

Volumn 100, Issue 6 A, 1996, Pages 52S-59S

  Holloway, William J ^a   Palmer, Darwin ^b  

^a MEDICAL CENTER OF DELAWARE   (United States)

^b VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFOPERAZONE; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; BACTERIUM ISOLATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HOSPITAL INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN INFECTION; URINARY TRACT INFECTION; ACUTE DISEASE; ANALYSIS OF VARIANCE; ARTICLE; BACTERIAL INFECTION; COMPARATIVE STUDY; CROSS INFECTION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; UNITED STATES;

ACUTE DISEASE; ANALYSIS OF VARIANCE; BACTERIAL INFECTIONS; CEFTAZIDIME; CEPHALOSPORINS; CROSS INFECTION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; UNITED STATES;

EID: 0030600122     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(96)00108-8     Document Type: Conference Paper

References (23)

1. The choice of antibacterial drugs. Med Lett Drugs Ther. 1992;36:49-56.
2. Johnson JR, Stamm WE. Urinary tract infections in women: diagnosis and treatment. Ann Intern Med. 1989;111:906-917.
3. Calandra T, Cometta A. Antibiotic therapy for gram-negative bacteremia. Infect Dis Clin North Am. 1991;5:817-834.
4. Neu HC. Pathophysiologic basis for the use of third-generation cephalosporins. Am J Med. 1990;88(suppl 4A):3-11.
5. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med. 1991;91(suppl 3B):72-75.
6. Kuikka A, Valtonen VV. Improved outcome of Staphylococcus aureus bacteremia. Infect Dis Clin Pract. 1994;3:282-287.
7. Bone RC. Gram-positive organisms and sepsis. Arch Intern Med. 1994;154:26-34.
8. Grassi GG, Grassi C. Cefepime: overview of activity in vitro and in vivo. J Antimicrob Chemother. 1993;32(suppl B):87-94.
9. Jacoby GA. Genetics of extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis. 1994;13(suppl 1):2-11.
10. Jones RN, Kehrberg EN, Erwin ME, Anderson SC. Prevalence of important pathogens and antimicrobial activity of parenteral drug at numerous medical centers in the United States. Diagn Microbiol Infect Dis. 1994;19:203-215.
11. Thornsberry C, Brown SD, Yee YC, Bouchillon SK, Marler JK, Rich T. Invitro activity of cefepime and other antimicrobials: survey of European isolates. J Antimicrob Chemother. 1993;32(suppl B):31-54.
12. Duval J, Soussy CJ, Acar JF, et al. In-vitro antibacterial activity of cefepime: a multicentre study. J Antimicrob Chemother. 1993;32(suppl B):55-62.
13. Sanders CC. Cefepime: the next generation? Clin Infect Dis. 1993;17:369-379.
14. Chong Y, Lee K, Kwon OH. In vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and other aerobic gram-negative bacilli. J Antimicrob Chemother. 1993;32(suppl B):21-30.
15. Toye BW, Scriver SR, Low DE. Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. J Antimicrob Chemother. 1993;32(suppl B):81-86.
16. Yee YC, Thornsberry C, Brown SD, Bouchillon SK, Marler JK, Rich T. A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 1993;32(suppl B):13-19.
17. Liu YC, Huang WK, Cheng DL. Antibacterial activity of cefepime in vitro. Chemotherapy. 1994;40:384-390.
18. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother. 1994;38:898-900.
19. Kieft H, Hoepelman AIM, Rozenberg-Arska M, et al. Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome. Antimicrob Agents Chemother. 1993;38:415-421.
20. Giamarellou H. Low-dosage cefepime treatment for serious bacterial infections. J Antimicrob Chemother. 1993;32(suppl B):123-132.
21. Hoepelman AIM, Kieft H, Aoun M. International comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. J Antimicrob Chemother. 1993;32(suppl B):175-186.
22. Steven RM, Teres D, Skillman JJ, Feingold DS. Pneumonia in an intensive care unit. Arch Intern Med. 1974;134:106-111.
23. Stamm WE, Martin SM, Bennett JV. Epidemiology of nosocomial infections due to gram-negative bacilli: aspects relevant to development and use of vaccines. J Infect Dis. 1977;136S(suppl):151-160.